Clinical Trial Update: Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ramucirumab or IMC-18F1 with docetaxel vs docetaxel alone as second-line therapy for urinary tract carcinomas, completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Renal Pelvis
• Carcinoma of Ureter
• Carcinoma of Urinary Tract
• Urethral Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• IMC-18F1
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma of Urinary Tract, Urethral Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-07-02